E 7820
Alternative Names: E-7820Latest Information Update: 15 Jan 2024
Price :
$50 *
At a glance
- Originator Eisai Co Ltd
- Class Antineoplastics; Indoles; Small molecules; Sulfonamides
- Mechanism of Action Angiogenesis inhibitors; Integrin alpha2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Colorectal cancer; Myelodysplastic syndromes
- Phase I/II Solid tumours
Most Recent Events
- 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Acute myeloid leukemia and Myelodysplastic syndrome presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
- 09 Dec 2023 Memorial Sloan Kettering Cancer Center in combination with Eisai completes a Phase II trial in Myelodysplastic syndromes, Chronic myelomonocytic leukaemia and Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater) in USA (PO) (NCT05024994)
- 10 Dec 2022 Updated adverse events data from a phase II trial in Acute myeloid leukaemia presented at 64th American Society of Hematology Annual Meeting and Exposition 2022 (ASH-Hem-2022)